Eli Lilly and Company (NYSE:LLY) Shares Acquired by Greenwich Wealth Management LLC

Greenwich Wealth Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 2.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,911 shares of the company’s stock after purchasing an additional 64 shares during the quarter. Greenwich Wealth Management LLC’s holdings in Eli Lilly and Company were worth $2,248,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Ninepoint Partners LP raised its stake in shares of Eli Lilly and Company by 31.3% in the 4th quarter. Ninepoint Partners LP now owns 1,179 shares of the company’s stock valued at $910,000 after purchasing an additional 281 shares in the last quarter. Envestnet Portfolio Solutions Inc. grew its position in shares of Eli Lilly and Company by 12.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 47,311 shares of the company’s stock valued at $36,524,000 after buying an additional 5,184 shares during the last quarter. Ascent Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $373,000. one8zero8 LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $649,000. Finally, Diversified Enterprises LLC grew its position in shares of Eli Lilly and Company by 3.0% during the 4th quarter. Diversified Enterprises LLC now owns 4,066 shares of the company’s stock valued at $3,139,000 after buying an additional 118 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.5 %

LLY stock opened at $813.55 on Friday. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a market cap of $771.38 billion, a PE ratio of 69.47, a P/E/G ratio of 1.40 and a beta of 0.34. The firm has a 50 day simple moving average of $830.81 and a 200 day simple moving average of $843.24. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on LLY shares. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Citigroup lowered their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Bank of America reaffirmed a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Morgan Stanley set a $1,146.00 target price on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,009.72.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares in the company, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.